tBE base editor
CorrectSequence Publishes New Base-Editing Trial Data
The peer-reviewed journal Cell Stem Cell published a study online on September 7 from CorrectSequence Therapeutics (Correctseq), a private, clinical-stage Chinese biotech, describing base-editing gene therapies CS-101 and CS-206 in nine patients with sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT) across several countries. The paper, co-authored with multiple Chinese academic and hospital institutions, extends…
